NFKB1 and breast cancer: These results encourage to also further investigate the potential anti-BC properties of Calebin A. In fact, a first study (Table 2) showed a dose-dependent inflammation- and thus proliferation-reduction in MCF-7 (BC cells) via suppression of TNF-α-induced NF-κB activation (98) by Calebin A. Furthermore, in another BC cell line, MDA-MB-231 the induction of osteoclastogenesis in mouse macrophage cells (RAW264.7) was observed, supporting the idea of bone loss as major secondary BC disease.